Findify

Find Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for demyelinating and autoimmune diseases. Based in Montreal and launched in 2020, the company leverages a proprietary platform focused on the development of transmembrane peptides that act as allosteric modulators of G protein-coupled receptors (GPCRs). Its lead program, tasronetide (FTX-101), is a first-in-class remyelinating agent targeting the NRP1/Plexin-A1 receptor complex to restore natural myelin repair. The company is currently advancing tasronetide into Phase 2 clinical trials for indications such as Chronic Optic Neuropathy and Multiple Sclerosis.